Positron Emission Tomography–Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001 | Zendy

Daniel O. Persky | Zendy; Hongli Li | Zendy; Deborah M. Stephens | Zendy; Steven I. Park | Zendy; Nancy L. Bartlett | Zendy; Lode J. Swinnen | Zendy; Paul M. Barr | Zendy; Jerome D. Winegarden | Zendy; Louis S. Constine | Zendy; Thomas J. FitzGerald | Zendy; John P. Leonard | Zendy; Brad S. Kahl | Zendy; Michael LeBlanc | Zendy; Joo Y. Song | Zendy; Richard I. Fisher | Zendy; Lisa M. Rimsza | Zendy; Sonali M. Smith | Zendy; Thomas P. Miller | Zendy; Jonathan W. Friedberg | Zendy

Open Access

Positron Emission Tomography–Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001

Author(s) -

Daniel O. Persky,

Hongli Li,

Deborah M. Stephens,

Steven I. Park,

Nancy L. Bartlett,

Lode J. Swinnen,

Paul M. Barr,

Jerome D. Winegarden,

Louis S. Constine,

Thomas J. FitzGerald,

John P. Leonard,

Brad S. Kahl,

Michael LeBlanc,

Joo Y. Song,

Richard I. Fisher,

Lisa M. Rimsza,

Sonali M. Smith,

Thomas P. Miller,

Jonathan W. Friedberg

Publication year - 2020

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.20.00999

Subject(s) - medicine , positron emission tomography , diffuse large b cell lymphoma , stage (stratigraphy) , lymphoma , clinical trial , nuclear medicine , oncology , radiology , paleontology , biology

Diffuse large B-cell lymphoma (DLBCL) presents as a limited-stage disease in 25% to 30% of patients, with better overall survival (OS) than that for advanced-stage disease but with continuous relapse regardless of treatment approach. The preferred treatment is abbreviated rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and radiation therapy. On the basis of promising results of positron emission tomography (PET)-directed treatment approaches, we designed a National Clinical Trials Network (NCTN) study to improve outcomes and decrease toxicity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research